Work

Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies

Year: 2011

Type: article

Abstract: Standard chemotherapy regimens are curative in only a subset of hematological malignancies, such as childhood acute lymphoblastic leukemia and certain subgroups of Hodgkin’s and non-Hodgkin’s lymph...

Source: Expert Review of Hematology

DOI: 10.1586/ehm.11.50

Authors: Beata Holkova, Steven Grant

Institutions: Virginia Commonwealth University Medical Center, Virginia Commonwealth University

Language: English

Topic: Ubiquitin and proteasome pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: G1353051725, G146968441, G3148123924, G3518617075, G354229063, Phase I Trial of Bortezomib and Romidepsin in CLL and Small Cell Lymphoma

OpenAlex ID: W1976702297

FWCI: 0.118

Cites: 22

Cited by: 3

Related to: 10